These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7663010)

  • 21. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
    Warzocha K; Bienvenu J; Ribeiro P; Moullet I; Dumontet C; Neidhardt-Berard EM; Coiffier B; Salles G
    Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.
    Christiansen I; Gidlof C; Kälkner K M; Hagberg H; Bennmarker H; Tötterman T
    Br J Haematol; 1996 Mar; 92(3):639-46. PubMed ID: 8616029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease.
    Pizzolo G; Vinante F; Nadali G; Ricetti MM; Morosato L; Marrocchella R; Vincenzi C; Semenzato G; Chilosi M
    Br J Haematol; 1993 May; 84(1):161-2. PubMed ID: 8101721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease.
    Pui CH; Ip SH; Thompson E; Wilimas J; Brown M; Dodge RK; de Hoyos RA; Berard CW; Crist WM
    Leukemia; 1989 Jul; 3(7):481-4. PubMed ID: 2786597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.
    Wenisch C; Myskiw D; Gessl A; Graninger W
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2122-6. PubMed ID: 7541802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.
    Vener C; Guffanti A; Pomati M; Colombi M; Alietti A; La Targia ML; Bamonti-Catena F; Baldini L
    Leuk Lymphoma; 2000 Apr; 37(3-4):333-9. PubMed ID: 10752984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis.
    Lim AG; Jazrawi RP; Ahmed HA; Levy JH; Zuin M; Douds AC; Maxwell JD; Northfield TC
    Hepatology; 1994 Oct; 20(4 Pt 1):882-8. PubMed ID: 7927229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of serum levels of soluble intercellular adhesion molecules-1 in patients with primary extranodal non-Hodgkin lymphomas.
    Lei KI; Johnson PJ
    Cancer; 2000 Sep; 89(6):1387-95. PubMed ID: 11002235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
    López-Lerma I; Estrach MT
    J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia.
    Turhan H; Erbay AR; Yasar AS; Aksoy Y; Bicer A; Yetkin G; Yetkin E
    Coron Artery Dis; 2005 Feb; 16(1):45-50. PubMed ID: 15654200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum levels of soluble intercellular adhesion molecule 1 in malignant lymphoproliferative disorders].
    Li D; Li G; Cui W
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):232-4. PubMed ID: 11601209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?
    Erturk K; Tastekin D; Bilgin E; Serilmez M; Bozbey HU; Sakar B
    Biomed Pharmacother; 2016 Feb; 77():86-91. PubMed ID: 26796270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of total serum cholesterol in patients with Hodgkin's disease.
    Muller CP; Trilling B; Steinke B
    Cancer; 1992 Feb; 69(4):1042-6. PubMed ID: 1735071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
    Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
    Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating soluble adhesion molecules in ANCA-associated vasculitis.
    Ara J; Mirapeix E; Arrizabalaga P; Rodriguez R; Ascaso C; Abellana R; Font J; Darnell A
    Nephrol Dial Transplant; 2001 Feb; 16(2):276-85. PubMed ID: 11158400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever.
    Direskeneli H; Ozdogan H; Korkmaz C; Akoglu T; Yazici H
    J Rheumatol; 1999 Sep; 26(9):1983-6. PubMed ID: 10493680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues.
    Krassas GE; Pontikides N; Doukidis D; Heufelder G; Heufelder AE
    Thyroid; 2001 Dec; 11(12):1115-22. PubMed ID: 12186498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
    Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
    Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.
    Magro F; Araujo F; Pereira P; Meireles E; Diniz-Ribeiro M; Velosom FT
    Dig Dis Sci; 2004 Aug; 49(7-8):1265-74. PubMed ID: 15387356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.